title: Long-term efficacy and safety of cyclosporin in severe adult atopic dermatitis.
abstract: A prospective, open, multicentre study was performed to investigate the efficacy and safety of long-term treatment with cyclosporin in adults with severe atopic dermatitis. Subjects were treated for a maximum of 48 weeks. For the first 8 weeks, cyclosporin was administered at 2.5 mg/kg per day. The dose was then adjusted according to response. Disease activity was monitored using the six-area, six-sign score and the proportion of skin involved. Pruritus and sleep disturbance were assessed using four-point scales. Response was further evaluated on a five-point scale. Adverse events, blood pressure and serum biochemistry were monitored. Tolerability was assessed on a five-point scale. One hundred subjects were enrolled and 65 completed 48 weeks of treatment. Withdrawals occurred due to remission (three), inadequate response (seven), protocol violations (11) and adverse events (14, of which seven were probably treatment related). Cyclosporin produced rapid and highly significant improvements in all indices of disease activity. Sixty-five subjects considered that they had shown a considerable improvement or complete clearance of disease. Most patients relapsed after cessation of treatment, but neither signs nor symptoms had returned to baseline severity 8 weeks later. Blood pressure and serum creatinine levels increased slightly, and in one subject renal impairment was a major factor contributing to withdrawal of the drug. Overall, 85 subjects rated the tolerability of cyclosporin as good or very good. The results indicate that cyclosporin has a place in the long-term treatment of severe atopic dermatitis provided that appropriate patients are selected and careful monitoring is performed.
authors.affiliation: Department of Dermatology, Walsgrave Hospital, Coventry, UK.
authors.forename: J
authors.initials: J
authors.lastname: Berth-Jones
authors.forename: R A
authors.initials: RA
authors.lastname: Graham-Brown
authors.forename: R
authors.initials: R
authors.lastname: Marks
authors.forename: R D
authors.initials: RD
authors.lastname: Camp
authors.forename: J S
authors.initials: JS
authors.lastname: English
authors.forename: K
authors.initials: K
authors.lastname: Freeman
authors.forename: C A
authors.initials: CA
authors.lastname: Holden
authors.forename: S C
authors.initials: SC
authors.lastname: Rogers
authors.forename: S
authors.initials: S
authors.lastname: Oliwiecki
authors.forename: P S
authors.initials: PS
authors.lastname: Friedmann
authors.forename: M S
authors.initials: MS
authors.lastname: Lewis-Jones
authors.forename: C B
authors.initials: CB
authors.lastname: Archer
authors.forename: B
authors.initials: B
authors.lastname: Adriaans
authors.forename: W S
authors.initials: WS
authors.lastname: Douglas
authors.forename: B R
authors.initials: BR
authors.lastname: Allen
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D002648:Child; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D003876:Dermatitis, Atopic / Q000188:drug therapy* / Q000473:pathology; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D012720:Severity of Illness Index
chemical_list: D007166:Immunosuppressive Agents; D016572:Cyclosporine